Literature DB >> 19657375

Intermittent androgen deprivation--questions remain.

Daniel Keizman1, Michael A Carducci.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19657375     DOI： 10.1038/nrurol.2009.145

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

Review 1.  EAU guidelines on prostate cancer.

Authors:  Axel Heidenreich; Gunnar Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Eur Urol       Date:  2007-09-19       Impact factor: 20.096

Review 2.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Authors:  D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

3.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Matthew R Smith
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

4.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Authors:  Maha Hussain; Catherine M Tangen; Celestia Higano; Paul F Schelhammer; James Faulkner; E David Crawford; George Wilding; Atif Akdas; Eric J Small; Bryan Donnelly; Gary MacVicar; Derek Raghavan
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.

Authors:  K Akakura; N Bruchovsky; S L Goldenberg; P S Rennie; A R Buckley; L D Sullivan
Journal:  Cancer       Date:  1993-05-01       Impact factor: 6.860

6.  Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer.

Authors:  Nicholas Bruchovsky; Laurence Klotz; Juanita Crook; Norman Phillips; Jonas Abersbach; S Larry Goldenberg
Journal:  Clin Genitourin Cancer       Date:  2008-03       Impact factor: 2.872

7.  Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.

Authors:  Naohide Sato; Koichiro Akakura; Shigeo Isaka; Hiroomi Nakatsu; Masashi Tanaka; Haruo Ito; Motoyuki Masai
Journal:  Urology       Date:  2004-08       Impact factor: 2.649

Review 8.  Andropause: symptom management for prostate cancer patients treated with hormonal ablation.

Authors:  Carrie A Thompson; Tait D Shanafelt; Charles L Loprinzi
Journal:  Oncologist       Date:  2003

9.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Authors:  Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson
Journal:  Eur Urol       Date:  2009-02-21       Impact factor: 20.096
  9 in total
  4 in total

Review 1.  An update on androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

2.  The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.

Authors:  Daniel Keizman; Peng Huang; Emmanuel S Antonarakis; Victoria Sinibaldi; Michael A Carducci; Samuel Denmeade; Jenny J Kim; Janet Walczak; Mario A Eisenberger
Journal:  Prostate       Date:  2011-03-22       Impact factor: 4.104

Review 3.  Management of patients with biochemical recurrence after local therapy for prostate cancer.

Authors:  Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci
Journal:  Hematol Oncol Clin North Am       Date:  2013-09-18       Impact factor: 3.722

Review 4.  Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Clark; Rodolfo Borges dos Reis; Antônio Carlos Lima Pompeo; Ubirajara Ferreira; Marcus Vinicius Sadi; Francisco Flávio Horta Bretas
Journal:  BMC Urol       Date:  2014-01-25       Impact factor: 2.264
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.